ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,139.83
0.75%
Dow Jones
38,239.66
0.40%
Gold vs US Dollar
2,337.935
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,406.00
-0.01%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Maxcyte Inc (MXCT)

  7. Maxcyte Inc (MXCT) News

Maxcyte (MXCT)

Maxcyte Inc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:MXCT
DateTimeSourceHeadlineSymbolCompany
10/04/202413:05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
03/04/202407:00RNS Regulatory NewsMaxCyte, Inc. Total Voting Rights and Block Listing ReturnLSE:MXCTMaxcyte Inc
02/04/202415:19Alliance NewsAlliance NewsTRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmoutLSE:MXCTMaxcyte Inc
02/04/202413:05RNS Regulatory NewsMaxCyte, Inc. Signing of Strategic Platform LicenseLSE:MXCTMaxcyte Inc
02/04/202407:00RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
20/03/202410:16RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
20/03/202410:05RNS Regulatory NewsMaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR DealingLSE:MXCTMaxcyte Inc
13/03/202411:54Alliance NewsAlliance NewsIN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%LSE:MXCTMaxcyte Inc
13/03/202407:05RNS Regulatory NewsMaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023LSE:MXCTMaxcyte Inc
13/03/202407:00RNS Regulatory NewsMaxCyte, Inc. Reports Q4 & FY 2023 Financial ResultsLSE:MXCTMaxcyte Inc
12/03/202420:05UK RegulatoryMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceLSE:MXCTMaxcyte Inc
06/03/202408:58RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
05/03/202420:43Alliance NewsAlliance NewsEARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profitLSE:MXCTMaxcyte Inc
05/03/202407:00RNS Regulatory NewsMaxCyte, Inc. Preliminary FY Results & 2024 GuidanceLSE:MXCTMaxcyte Inc
04/03/202421:05UK RegulatoryMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsLSE:MXCTMaxcyte Inc
01/03/202417:57RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
29/02/202409:21RNS Regulatory NewsMaxCyte, Inc. Exercise of options and PDMR dealingLSE:MXCTMaxcyte Inc
26/02/202407:00RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
09/02/202413:05RNS Regulatory NewsMaxCyte, Inc. Notice of ResultsLSE:MXCTMaxcyte Inc
09/02/202413:05UK RegulatoryMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesLSE:MXCTMaxcyte Inc
01/02/202409:24RNS Regulatory NewsMaxCyte, Inc. Total Voting RightsLSE:MXCTMaxcyte Inc
31/01/202407:00RNS Regulatory NewsMaxCyte, Inc. Director/PDMR ShareholdingLSE:MXCTMaxcyte Inc
30/01/202414:29RNS Regulatory NewsMaxCyte, Inc. Holding(s) in CompanyLSE:MXCTMaxcyte Inc
30/01/202413:58Alliance NewsAlliance NewsIN BRIEF: MaxCyte signs licencing deal with cell therapy company WugenLSE:MXCTMaxcyte Inc
30/01/202413:05RNS Regulatory NewsMaxCyte, Inc. Signing of Strategic Platform LicenseLSE:MXCTMaxcyte Inc
30/01/202413:05UK RegulatoryMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersLSE:MXCTMaxcyte Inc
29/01/202417:56Alliance NewsAlliance NewsIN BRIEF: MaxCyte chief scientific officer leaves firmLSE:MXCTMaxcyte Inc
29/01/202416:52RNS Regulatory NewsMaxCyte, Inc. TR-1: Notification of major holdingsLSE:MXCTMaxcyte Inc
29/01/202407:00RNS Regulatory NewsMaxCyte, Inc. Filing of Form 8-KLSE:MXCTMaxcyte Inc
23/01/202418:39Alliance NewsAlliance NewsTRADING UPDATES: Esken's Southend Airport faces further allegationsLSE:MXCTMaxcyte Inc
 Showing the most relevant articles for your search:LSE:MXCT

Your Recent History

LSE
MTRO
Metro Bank
LSE
ENET
Ethernity Networks
LSE
CHLL
Chill Brands
LSE
SBTX
Skinbiotherapeutics
LSE
AAU
Ariana Resources
LSE
AGL
Angle
LSE
TYM
Tertiary Minerals
LSE
SOLG
Solgold
LSE
BIRD
Blackbird
LSE
GKP
Gulf Keystone Petroleum
LSE
GOLD
LSE
BOO
Boohoo
LSE
MIRI
Mirriad Advertising
LSE
LGEN
Legal & General
LSE
ZOO
Zoo Digital
LSE
SAR
Sareum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved